We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+4.73%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.11B
AUM Growth
+$59.7M
Cap. Flow
+$37M
Cap. Flow %
3.34%
Top 10 Hldgs %
63.03%
Holding
52
New
19
Increased
6
Reduced
15
Closed
2

Top Buys

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$57.2M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$26.2M
3
AKCA
Akcea Therapeutics Inc
AKCA
+$22.8M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$20.7M
5
RUBY
Rubius Therapeutics, Inc
RUBY
+$13.5M

Top Sells

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$55.8M
2
ASND icon
Ascendis Pharma A/S
ASND
+$25.9M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$20.9M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$17.7M
5
WVE icon
Wave Life Sciences
WVE
+$16.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.05%
2 Miscellaneous 12.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABUS icon
26
Arbutus Biopharma
ABUS
$1B
$11.6M 1.05%
+1,231,800
New +$12.2M
IRWD icon
27
CALL
Ironwood Pharmaceuticals
IRWD
$682M
$10.5M 0.94%
677,714
-11,940
-2% -$189K
SPRO icon
28
Spero Therapeutics
SPRO
$69.9M
$9.38M 0.85%
+892,741
New +$10.4M
IMDZ
29
DELISTED
Immune Design Corp.
IMDZ
$7.74M 0.7%
2,241,900
-2,195,700
-49% -$8.24M
ZLAB icon
30
Zai Lab
ZLAB
$2.93B
$6.82M 0.61%
+350,000
New +$7.59M
NGNE icon
31
Neurogene
NGNE
$732M
$6.64M 0.6%
113,294
+55,794
+97% +$3.29M
ELAN icon
32
Elanco Animal Health
ELAN
$12B
$6.63M 0.6%
+190,000
New +$6.68M
SGMO
33
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$5.82M 0.52%
343,231
-1,166,440
-77% -$17.7M
ACHN
34
DELISTED
Achillion Pharmaceuticals
ACHN
$5.76M 0.52%
1,564,080
-2,323,327
-60% -$6.92M
ASMB icon
35
CALL
Assembly Biosciences
ASMB
$694M
$5.5M 0.5%
12,342
– –
MRSN
36
DELISTED
Mersana Therapeutics
MRSN
$4.96M 0.45%
+19,825
New +$6.64M
KDMN
37
DELISTED
Kadmon Holdings, Inc.
KDMN
$4.95M 0.45%
1,480,870
-1,019,130
-41% -$3.61M
IONS icon
38
Ionis Pharmaceuticals
IONS
$10.1B
$3.73M 0.34%
+72,326
New +$3.4M
TRAW icon
39
Traws Pharma
TRAW
$9.07M
$3.67M 0.33%
1,333
– –
TECX
40
Tectonic Therapeutic
TECX
$696M
$3.56M 0.32%
+5,721
New +$2.54M
JNCE
41
CALL
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$3.23M 0.29%
+497,400
New +$3.7M
CRVS icon
42
Corvus Pharmaceuticals
CRVS
$1.19B
$3.02M 0.27%
351,401
-98,999
-22% -$990K
WVE icon
43
Wave Life Sciences
WVE
$993M
$2.24M 0.2%
44,841
-368,030
-89% -$16.6M
CNST
44
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$1.88M 0.17%
+280,000
New +$2.67M
FTSV
45
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$1.48M 0.13%
+99,000
New +$1.48M
CHMA
46
DELISTED
Chiasma, Inc. Common Stock
CHMA
$1.37M 0.12%
+379,753
New +$794K
INFI
47
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.25M 0.11%
462,068
+50,068
+12% +$104K
APTX
48
DELISTED
Aptinyx Inc. Common Stock
APTX
$1.19M 0.11%
41,037
– –
ARVN icon
49
Arvinas
ARVN
$600M
$844K 0.08%
+50,000
New +$823K
PHXM
50
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$590K 0.05%
6,957
-8,439
-55% -$879K
1
2
3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2018 Portfolio in Review

As of Q3 2018, EcoR1 Capital held 52 positions worth $1.11B, up 5.7% from $1.05B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

EcoR1 Capital deployed $37M of net new capital in Q3 2018, opening 19 new positions and adding to 6 existing holdings. Its largest new stake was Spark Therapeutics, Inc. Common Stock: 837,048 shares worth $45.7M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 87% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $25.9M trimmed.

  • EcoR1 Capital's largest Q3 2018 buy was Spark Therapeutics, Inc. Common Stock: 837,048 shares worth $45.7M.
  • EcoR1 Capital added most to Dicerna Pharmaceuticals, Inc. in Q3 2018, an estimated $12.2M increase.
  • EcoR1 Capital's biggest Q3 2018 reduction was Ascendis Pharma A/S, cutting an estimated $25.9M.
  • EcoR1 Capital fully exited Madrigal Pharmaceuticals in Q3 2018, selling an estimated $55.8M.
  • EcoR1 Capital's ten largest holdings make up 63% of its $1.11B portfolio in Q3 2018.
  • EcoR1 Capital opened 19 new positions and closed 2 in Q3 2018.
  • EcoR1 Capital's portfolio value rose 5.7% quarter-over-quarter to $1.11B.

Based on EcoR1 Capital's 13F filing for Q3 2018, filed 14 Nov 2018.